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Background: Post-weaning multisystemic wasting syndrome (PMWS) associated with PCV2 is one of the most
costly diseases currently faced by the swine industry. The development of effective vaccines against PCV2 infection
has been accepted as an important strategy in the prophylaxis of PMWS.
Methods: In the present study, a PK-15 cell-adapted formalin-inactivated prototype vaccine candidate was
prepared using a strain of PCV2 from China. Inactivation of the virus was accomplished using a standard formalin
inactivation protocol. The protective properties of the inactivated PCV2 vaccine were evaluated in piglets. Ten
28-day-old pigs were randomly assigned to two groups, each with five. Group 1 was vaccinated intramuscularly
with the inactivated virus preparation; Group 2 received sterile PBS as a placebo. By 28 days post-vaccination (DPV),
Groups 1 and 2 were challenged intranasally and intramuscularly with 5 × 107 TCID50 of a virulent PCV2 isolate.
Results: The vaccinated pigs seroconverted to PCV2 and had high levels of serum antibodies to PCV2 at 28 days
after vaccination, whereas the control pigs remained seronegative. No significant signs of clinical disease were
recorded following the challenge with PCV2, but moderate amounts of PCV2 antigen were detected in most
lymphoid organs of the control pigs. PCV2 was detected in two out of the five vaccinated pigs. Furthermore,
pathological lesions and viremia were milder in the vaccinated group.
Conclusions: The obtained results indicate that the inactivated PCV2 virus vaccine with an oil adjuvant induce an
immunological response in pigs that appears to provide protection from infection with PCV2. The vaccine,
therefore, may have the potential to serve as a vaccine aimed to protect pigs from developing PMWS.
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Formalin-inactivated vaccineBackground
Post-weaning multisystemic wasting syndrome (PMWS)
was first observed in piglets of a high-health herd in
western Canada in 1991 [1], and similar disorders were
subsequently observed in herds in Europe, the United
States and Asia [2-7]. PMWS primarily affects pigs be-
tween 5 and 18 weeks of age [8]. The clinical signs of this
syndrome include progressive weight loss, unthriftiness,* Correspondence: heqigai@yahoo.com
†Equal contributors
1State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural
University, Wuhan 430070, China
Full list of author information is available at the end of the article
© 2012 Yang et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the orpaleness of the skin and dyspnea, and, less frequently,
diarrhea and jaundice. Grossly, the main features of
PMWS are generalized lymphadenopathy (with the
superficial inguinal, submandibular, mesenteric and
mediastinal lymph nodes being the most affected) and
tan-mottled, non-collapsed lungs [9]. Histopatho-
logical findings are characterized by lymphocyte deple-
tion of follicular and interfollicular areas together with
macrophage infiltration of lymphoid tissues, interstitial
pneumonia, hepatitis and nephritis [9]. The mortality rate
may vary from 1 to 2% up to 30% in complicated cases [5].
The accumulated evidence indicates that PCV2 is the
major pathogen in the etiology of PMWS [10-13].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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swine diseases, such as porcine dermatitis and
nephropathy syndrome (PDNS), porcine respiratory
disease complex (PRDC) and reproductive failure,
which are now collectively referred to as PCVAD or
PCV2-associated diseases, a name that the American
Association of Swine Veterinarians (AASV) uses to
group together all the diseases attributed to PCV2,
including PMWS [14]. PCV2 is a non-enveloped, sin-
gle-stranded, circular DNA virus with a 1.76-kb ambi-
sense genome [15]. The PCV2 genome is assumed to
have 11 potential open reading frames (ORF1-11)
[16]. Previous studies have demonstrated that ORF1,
-2 and −3 encode a 35.7 kDa replication (Rep) pro-
tein involved in virus replication [17], a 27.8 kDa cap-
sid (Cap) protein involved in PCV2 immunogenicity
[18-20] and a protein involved in PCV2-induced
apoptosis [21], respectively. Immunization against
PCV2 has been studied intensely and found to be the
most effective strategy for protecting pigs against
PCV2 infection. Over the years, various PCV2 vac-
cines, including DNA vaccines [22,23], chimeric
PCV1-2 vaccines [24] and subunit vaccines [25], have
been described for the control of PCV2 infections.
Although both DNA vaccination and subunit vaccin-
ation based on the ORF2 gene have shown relatively
satisfactory immunization against PCV2, DNA vaccin-
ation is not suitable for clinical application because of
the possibility of carcinogenesis [26]. Subunit vaccin-
ation is safer but not suitable for farmers in develop-
ing countries due to its high cost. Inactivated
vaccines are theoretically advantageous because they
represent a complex mixture of viral antigens closely
resembling the native virion. Formalin is known to
interact and induce the cross-linking of viral proteins,
leading to the loss of virus infectivity. The formalin
inactivation of a virus has been successfully used to
develop safe and efficacious human and veterinary
vaccines since 1955 [27]. The use of formalin inactiva-
tion for virus vaccine development is attractive from a
safety perspective as the virus cannot revert to a virulent
form, because there is no virus replication during
immunization. The use of formalin to inactivate viruses is
also attractive from a manufacturing perspective as the in-
activation process is relatively simple to develop.
Therefore, we prepared a PK-15 cell culture-derived,
formalin-inactivated prototype vaccine candidate for
PCV2. Animal experiments were designed to evaluate
the immunogenicity and efficacy of the inactivated
PCV2 vaccine in combination with an oil adjuvant in
conventional pigs following intramuscular (IM) adminis-
tration. The protective efficacy of the immunological re-
sponse was evaluated by challenge with PCV2 via the
intranasal (IN) and intramuscular (IM) routes.Methods
Virus
The WuHan strain of PCV2 (GenBank: FJ 598044) was
used to prepare both the vaccine and the challenge in-
oculum for the animals. The virus was propagated in
porcine kidney cells (PK-15) free of PCV1 contamination
and grown in Minimal Essential Medium (MEM) con-
taining 10% fetal bovine serum. The titer of the virus
stock was 107 TCID50/ml.
Vaccine preparation
The PCV2 was produced according to the methods
described by Tischer et al. [28], with minor modifica-
tions. Briefly, the PCV2 WuHan strain was inoculated
into PK-15 cells by one-step inoculation and incubated
at 37 °C with 5% CO2 in MEM containing 10% fetal bo-
vine serum. One day after seeding, the medium was
removed, and the cultures were incubated with 300 mM
D-glucosamine in Hank’s salt solution (HSS) for 30 min
at 37°C in a volume sufficient to cover the monolayer.
Thereafter, the treated PK-15 cell cultures were incu-
bated in growth medium for two additional days in
MEM containing 2% fetal bovine serum at 37°C with 5%
CO2. The inoculated cells were frozen and thawed three
times. After centrifugation at 5000 × g for 20 min, the
supernatant was titered and then inactivated by incuba-
tion with formalin at a 0.3% final concentration for
48 hours at 37°C. Virus inactivation was confirmed by
the inoculation of the formalin-treated samples into PK-
15 cells. The formalin in the samples was then neutra-
lized by the addition of one part 0.2% (w/v) sodium
metabisulfite to 100 parts of vaccine. The titer of the
virus suspension prior to inactivation was 107 TCID50/
ml. The inactivated viral suspension was then mixed
with an oil adjuvant (MARCOL 52, EXXonMobile, USA)
at an appropriate ratio.
Animals and housing
Ten healthy, weaned, three-week-old crossbred piglets
were obtained from a pig farm that was negative for
PCV2 and PRRSV infections. The selected animals were
transported to the animal facilities at the Huazhong
Agricultural University and allowed to acclimatize for
seven days before the PCV2 vaccination. All experi-
mental protocols were approved by the Research Ethics
Committee of College of Veterinary Medicine, Huazhong
Agricultural University, Hubei, China (No. 2009–0012).
The animals were randomized into two groups with five
pigs each and raised separately in two isolation rooms
with individual ventilation. The pigs were provided com-
mercial diets and water ad libitum. During that period,
the animals were weighed and bled to assess their sero-
logical and virological status to PCV2, and all piglets
were confirmed to have neither serological nor
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to the vaccination (data not shown).
Experimental design and sample collection
After arriving at the animal facilities, the piglets were
given an identity and distributed into two groups with
stratification by their weight, namely Group 1 and
Group 2. The animal care was provided under an Insti-
tutional Animal Care and Use Committee approved
protocol. At 4 weeks of age, each piglet in Group 1 was
intramuscularly injected with 2.0 ml of prepared inacti-
vated PCV2 vaccine on the right side of the neck,
whereas each piglet in Group 2 received 2.0 ml of sterile
PBS as a placebo. Next, four weeks after the immunization
(8 weeks of age), all pigs were challenged with 5 ml (2.5 ml
intranasally and 2.5 ml intramuscularly) of the WuHan
strain of PCV2 at a dose of 107 TCID50/ml. After the in-
oculation, the pigs were monitored for 28 days. Dur-
ing this period, the pigs were clinically examined, and
rectal temperatures were recorded on a daily basis.
Body weight was measured before the immunization,
at challenge and at the time of necropsy. The relative
daily weight gains (expressed as daily weight gains/
primary body weight, RDWG) were determined. Blood
samples were collected from the vena cava at the time
of the vaccination and at weeks 1, 2 and 3 post-
vaccination (PV), at the time of challenge and on a
weekly basis thereafter. Sera were obtained and stored
at −80°C until the serological and virological test were
performed. Twenty-eight days after the challenge, the
animals were euthanized with an intravenous overdose
of sodium pentobarbital, and a complete necropsy was
performed. All tissue collection procedures were
performed according to the protocols approved by the
Hubei Province PR China for Biological Studies Ani-
mal Care and Use Committee. Macroscopic and
microscopic lesions were compared between the
groups. The amount of PCV2 antigen in the lymphoid
tissues was determined by immunohistochemistry
(IHC).
Quantitative real-time PCR for evaluation of viremia
DNA extraction from the serum samples collected on
the day of challenge and on DPC 7, 14, 21 and 28
was performed using the E.Z.N.A.TM Viral DNA Kit
(OMEGA, USA) according to the manufacturer’s
instructions. The DNA was used to quantify the PCV2
genomic DNA copy numbers by real-time PCR. Gen-
Bank entry FJ598044 was used for the primer and probe
design. The Cap gene region (corresponding to nucleo-
tides 1033–1734 bp of the whole PCV2 genome)
[19,29,30] was chosen for the primer and probe design
because it has a lower nucleotide homology with porcine
circovirus type 1 (PCV1) than ORF1 (~65%) [31]. Theforward (5'-CCAGGAGGGCGTTCTGACT-3') and re-
verse (5'-CGTTACCGCTGGAGAAGGAA-3') primers
and probe (5'-AATGGCATCTTCAACACCCGCCTCT-
3') were designed using the Primer Express v.1.5 soft-
ware (ABI Prism 7500 User’s Guide, Applied Biosystems,
Foster City, CA, USA). The primers and probe were
selected to work under universal conditions (ABI Prism
7500 User’s Guide, Applied Biosystems, USA). The probe
was labeled on the 5' end with FAMTM (6-carboxyfluor-
escein) and on the 3' end with TAMRATM (6-carboxyte-
tramethylrhodamine). The PCR reaction contained a
final concentration of 1× THUNDERBIRD Probe qPCR
Mix (TOYOBO, Japan), 0.3 μM each primer, 0.2 μM
Taqman Probe, 0.04 μl of 50× ROX reference dye and
DNA equivalent to that of 1 ml serum as the template.
Autoclaved nanopure water was added to bring the final
volume to 25 μl. All reactions were conducted in tripli-
cate on an ABI7500 (Applied Biosystems). The PCR pro-
gram consisted of one cycle of 95°C for 1 min and
40 cycles of 95°C for 15 s and 60°C for 1 min. For a
standard curve, serial dilutions of plasmid pORF2 (the
ORF2 gene cloned into the pMDTM 18-T Vector) were
used to quantify the virus genomic copy number. The
numbers of virus copies for each sample were presented
as the mean value of triplicate reactions.Serological tests
Cap protein-specific antibodies were determined with an
endpoint ELISA using the recombinant Cap protein
antigen as described previously [32]. The titers were
expressed as the reciprocal of the highest dilution of sera
producing ratio values of 2:1.Histopathology
Formalin-fixed, paraffin-embedded tissue samples were
cut into 4 μm thick slices, stained with hematoxylin-
eosin and examined for lesions compatible with PMWS.
The sections for histopathological examination were
taken from lung and lymphoid tissues, including the
lymph nodes (mesenteric and superficial inguinal), ton-
sil, and spleen. The tissues were examined in a blinded
fashion and given a subjective score for the severity of
the lesions. The lung scores ranged from 0 (normal) to 3
(severe lymphohistiocytic interstitial pneumonia).
Lymphoid tissues were evaluated for the presence of
lymphoid depletion, ranging from 0 (normal) to 3 (se-
vere), and for histiocytic inflammation and the replace-
ment of follicles, ranging from 0 (normal) to 3 (severe)
[32]. The overall microscopic lymphoid lesion score was
the average of the five studied tissues (lung, tonsil,
spleen, and the mesenteric and superficial inguinal
lymph nodes).
Table 2 PCV2 prevalence in the serum of pigs following
intranasal and intramuscular inoculations with PCV2, and
the mean viral load of the PCV2-positive pigs (log10)
Groups Day post-challenge
7 17 21 28
PCV2 in serum
Vaccinated group 3 of 5 3 of 5 2 of 5 0 of 5
Control group 5 of 5 5 of 5 5 of 5 5 of 5
Viral load in positive pigs
Vaccinated group 7.69 ± 0.11 7.67 ± 0.22 7.76 ± 0.26 0.00 ± 0.00
Control group 8.31 ± 0.40 8.41 ± 0.91 8.77 ± 0.55 7.72 ± 0.55
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IHC for the detection of PCV2-specific antigens was per-
formed on lymphoid tissues, including lymph nodes (mes-
enteric and superficial inguinal), tonsil, and spleen
collected during the necropsy at 28 DPC. A rabbit poly-
clonal antiserum against PCV2 was used for IHC follow-
ing procedures described previously [33]. The amount of
PCV2 antigen distributed in the tissues was scored in a
blinded fashion by assigning a score ranging from 0 for no
signal to 3 for a strong positive signal. The mean group
score was determined for each tissue and compared be-
tween groups.Statistical analysis
The statistical analysis was performed by one-way analysis
of variance using SPSS version 17.0 (SPSS). The results
were considered to be statistically significant for P < 0.05.Results
Clinical presentation
None of the animals developed clinical signs compatible
with PMWS during the entire experiment. The number of
days in which the rectal temperature exceeded 40.0°C and
the relative daily weight gain (expressed as the daily
weight gain/primary body weight, RDWG) were recorded.
As shown in Table 1, no significant differences in the body
weight or rectal temperature were observed between the
groups at any of the sampling times.Incidence and amount of PCV2 DNA in serum
PCV2 DNA was not detected in any of the serum samples
on the day of the challenge. The log transformed group
mean amounts of PCV2 DNA for both groups are sum-
marized in Table 2. In the challenge-control group, all pigs
had PCV2 viremia, which persisted for at least 28 days.
However, in the vaccination-challenge group three out of
five pigs had PCV2 viremia that persisted for 21 days after
the PCV2 challenge. At 28 days after the PCV2 challenge,
no viremia was observed. In addition, compared with the
challenge-control pigs, those in the vaccination-challenge
group exhibited a reduction in the level of viremia, al-
though this difference was not significant. This result indi-
cated that the viremia presented in the vaccination-
challenge group was lighter than that in the challenge-






Vaccinated group 0 14.98 ±
Control group 0.40 ± 0.55 15.16 ±Humoral response
The evolution of the ELISA titers to PCV2 in the vacci-
nated and non-vaccinated pigs is displayed in Figure 1.
Both groups were seronegative for PCV2 when vacci-
nated on day 0. At the time of the challenge, which was
28 days later, the vaccinated pigs had seroconverted to
PCV2 and had significantly (p < 0.05) higher titers of
antibodies against PCV2 than the control pigs. Both
groups had increased levels of serum antibodies against
PCV2 following the challenge, and the non-vaccinated
control pigs seroconverted to PCV2 between 14 and
28 days post-challenge (days 42 to 56).
Histopathological lesions
To investigate the protective efficacy of the inactivated
PCV2 vaccine, we compared the pathological changes of
the lung and lymphoid tissues between the groups. All
pigs in the control group had mildly to moderately
thicker alveolus walls (Figure 2A) in their lungs on day
28 post-challenge (day 56), with a total score of 9. These
pigs also had mild to moderate histiocytic replacement in
the lymphoid tissues (Figure 2C), with a total score of 8.
In contrast, no signs of disease were recorded in four of
the five vaccinated pigs (Figure 2B and 2D). The fifth vac-
cinated pig had a score of 1 in the lungs and 1 in the
lymphoid tissues.
Detection of the PCV2 antigen in tissues
At necropsy (DPC 28), the incidences of the PCV2 anti-
gen as determined by IHC for the immunized and non-
vaccinated pigs, respectively, were as follows: 2/5 and 5/
5 in the superficial inguinal lymph node sections, 2/5
and 5/5 in the mesenteric lymph node sections, 1/5 andnasal and intramuscular inoculations with PCV2
Body weight Relative daily
weight gainlenge 28 days pc
1.09 27.96 ± 0.84 0.0311 ± 0.0035
1.32 27.12 ± 0.90 0.0284 ± 0.0036
Figure 1 PCV2-specific antibody detection by ELISA. ELISA assay for PCV2-specific antibodies in the serum of vaccinated and non-vaccinated
pigs from day 28 pre-challenge to day 28 post-challenge. (**) Indicates significantly (P < 0.01) higher PCV2-specific antibody titers in the
vaccinated pigs than in the challenge control pigs.
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sections (Table 3).The amounts of PCV2 antigen in the
immunized pigs were significantly lower than in the
non-vaccinated pigs in the superficial inguinal lymph
nodes and mesenteric lymph nodes (P < 0.01). In
addition, compared with the challenge-control group
pigs, those in the vaccination-challenge group exhibited
a reduction in the amounts of PCV2 antigen in theFigure 2 Histological lesions found in the PCV2-challenged pigs. Seve
challenge-control group (A). Severe infiltration with epithelium-like macrop
control group (C). There were no clear histological lesions in the lungs (B)tonsils and spleen, although these differences were not
significant.
Discussion
Post-weaning multisystemic wasting syndrome (PMWS)
is recognized as a major disease problem of economic
importance in many pig-producing areas of the world
[5,8]. It can cause significant levels of mortality in manyrely thicker alveolus walls were examined in the lung of pigs in the
hages (↑) was examined in the lymph nodes of pigs in the challenge-
or lymph nodes (D) in four out of the five vaccinated pigs.
Table 3 Demonstration of PCV2 by immunohistochemistry at the necropsy performed 28 days after the intranasal and
intramuscular inoculations of the pigs with PCV2, shown as the number of PCV2-positive pigs and mean scores
Groups Body organ
Superficial inguinal lymph nodes Mesenteric lymph nodes Tonsils Spleen
Presence of PCV2
Vaccinated group 2 of 5 2 of 5 1 of 5 1 of 5
Control group 5 of 5 5 of 5 4 of 5 3 of 5
Mean score
Vaccinated group 0.40 ± 0.55 0.40 ± 0.55 0.20 ± 0.45 0.20 ± 0.45
Control group 2.40 ± 0.55* 2.00 ± 0.71* 1.00 ± 0.71 0.80 ± 0.84
Values in parentheses are the mean estimated amounts of the PCV2 antigen in lymphoid tissues (range: 0, no antigen detected; 3, high amounts of antigen).
* indicates a difference in the mean value scores between the groups (P < 0.05).
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to contribute to this disease, there is no doubt that the
expression of the clinical disease is dependent on the
presence of PCV2 [34,35]. The development of effective
vaccines against PCV2 infection has been accepted as a
strategy for the prophylaxis of PMWS. Maternal anti-
bodies against PCV2 have been shown to be present in
3-week-old pigs, which gradually decrease to a very low
level in 11-week-old pigs [36]. The low levels of anti-
bodies against PCV2 ensure that the pigs are unable to
handle a PCV2 infection, leading them to develop
PMWS [37,38]. To create a viable PCV2 vaccine ap-
proach, a vaccination method should be designed to in-
duce immunity in piglets prior to the time-point when
the weaning maternal immunity makes the piglets sus-
ceptible to PCV2 infection. The lack of a consistent, pre-
cise and reproducible model of PMWS [14] is one of the
main drawbacks for the experimental evaluation of
PCV2 vaccines. Therefore, the assessment of vaccine ef-
ficacy in terms of protection against clinical disease was
not feasible. This situation applies not only to this study
but also to earlier ones in which only subclinical infec-
tions were developed [24,39-41]. As performed in those
studies, the vaccine efficacy may be validated by evaluat-
ing some parameters related to PCV2 infection, such as
viremia, the presence of microscopic PMWS-like lesions
and the viral load in tissues, or by determining the abil-
ity of the vaccine to induce an immune response.
Reduced PCV2 viremia was observed in PCV2 vaccine
studies in PCV2-negative pigs under experimental con-
ditions [39,41,42]. In the present study, the experimental
model using PCV2 alone as an inoculum did not suc-
ceed in causing PMWS; however, we examined the
PCV2 levels in the sera of pigs by real-time PCR at dif-
ferent times after the challenge, and the results indicated
that the proportion of viremic pigs, the days with
viremia and the viremia levels in the serum were signifi-
cantly reduced in the vaccination-challenge pigs com-
pared with their challenge-control counterparts.
Additionally, the PCV2 antigen was detected in low-to-high amounts in lymph node, tonsil, and spleen tissues
of the non-vaccinated pigs but not those of the vacci-
nated pigs, with the exception of one pig. This observa-
tion suggests that the inactivated PCV2 vaccine can
partially prevent PCV2 viremia and significantly reduce
the amount of PCV2 virus in the lymphoid tissues,
which are important factors in the pathogenesis of
PCV2-associated diseases [36,43]. PCV2-specific anti-
bodies have been generally accepted to be associated
with protection because field evidence has suggested
that the decrease in antibodies contributes to the devel-
opment of PMWS [2,8,44]. In this study, the ELISA
results showed that the level of antibodies against PCV2
in the serum of vaccinated pigs gradually increased and
that the seroconversion to PCV2-specific antibodies was
detected in two pigs at 14 DPV and all five pigs by 21
DPV. These results confirmed that the inactivated PCV2
whole-virus vaccine with an oil adjuvant could elicit a
high level of humoral immune response in swine. The
PCV2-challenge in this study was performed using both
intramuscular and intranasal routes, which is in contrast
to other groups that used the intranasal route only
[45,46]. The combination of the intranasal and intramus-
cular routes of inoculation was found to be successful in
obtaining a uniform PCV2 infection level in the pigs
[47-49]. We chose to perform both because of the
increased likelihood that not all the pigs inhale an equal
amount of inoculum due to sneezing and/or labored
breathing at the time of inoculation when using only the
intranasal route. This approach was performed to ensure
that all pigs received a certain amount of the virus and
to ensure that the infection was successful. The mean
scores of the microscopic lesions in the lung, lymph
node, spleen, and tonsil tissues of the vaccinated groups
showed that the lesions were less severe (P < 0.05) than
those of the non-vaccinated group. These results indi-
cate that the inactivated PCV2 vaccine may be effective
in protecting pigs from PCV2-associated diseases, but
further studies are required to ensure the efficacy of the
vaccine.
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In conclusion, the results obtained indicate that an inac-
tivated PCV2-virus vaccine with an oil adjuvant induces
an immunological response in pigs that appears to pro-
tect the pigs from PCV2 infection. The vaccine may thus
have the potential to serve as a vaccine to protect pigs
from the development of PMWS.
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